- Home
- QLYS vs TARS Comparison
QLYS vs TARS Comparison
Compare QLYS & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QLYS | TARS |
|---|---|---|
| Founded | 1999 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.7B |
| IPO Year | 2012 | 2020 |
Fundamental Metrics
Financial Performance| Metric | QLYS | TARS |
|---|---|---|
| Price | $158.52 | $61.02 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 6 |
| Target Price | ★ $133.08 | $89.00 |
| AVG Volume (30 Days) | 728.0K | ★ 1.1M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 16.99 | ★ 48.21 |
| EPS | ★ 1.42 | N/A |
| Revenue | $321,607,000.00 | ★ $451,360,000.00 |
| Revenue This Year | $9.97 | $56.43 |
| Revenue Next Year | $7.15 | $30.19 |
| P/E Ratio | $109.08 | ★ N/A |
| Revenue Growth | 15.32 | ★ 146.71 |
| 52 Week Low | $74.51 | $40.55 |
| 52 Week High | $167.86 | $85.25 |
Technical Indicators
Market Signals| Indicator | QLYS | TARS |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout QLYS Qualys Inc.
Qualys is a cloud security and compliance solutions provider that helps businesses identify and manage their security risks and compliance requirements. The California-based company has more than 10,000 customers worldwide, the majority of which are small- and medium-size businesses. Qualys was founded in 1999 and went public in 2012.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.